Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | FSHR | P23945 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948816 | 0.84 | KIT (1.00) | KITMAPK14LCKSRCKDR | |
| SCHEMBL2950933 | 0.79 | KIT (0.68) | KITMAPK14LCKSRCKMT2A | |
| SCHEMBL31004385 | 0.78 | KIT (1.00) | KITMAPK14LCKSRCKDR | |
| SCHEMBL2952365 | 0.78 | KIT (1.00) | KITMAPK14LCKSRCKDR | |
| SCHEMBL2950360 | 0.78 | KIT (0.72) | KITMAPK14LCKSRCNAMPT | |
| SCHEMBL2948747 | 0.78 | KIT (1.00) | KITMAPK14LCKSRCKDR | |
| SCHEMBL2951997 | 0.77 | KIT (0.66) | KITMAPK14LCKSRCKMT2A | |
| SCHEMBL2942535 | 0.76 | KIT (0.90) | KITMAPK14LCKSRCKDR | |
| SCHEMBL2950446 | 0.76 | KIT (0.71) | KITMAPK14LCKSRCKDR | |
| SCHEMBL13213711 | 0.74 | SMN1; SMN2 (0.69) | KMT2ASMN1; SMN2USP2HPGDNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | KIT 7/4885MAPK14 525/4885LCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.